The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.

We’ve launched a first-of-its-kind app to help you find out where your generic drugs come from and see the track records of ...

For many, these price reductions may represent a critical step in improving access to essential medications, especially as ...

Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...

Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid ...